Cellectis Reports Share Capital and Voting Rights as of July 31, 2025
ByAinvest
Friday, Aug 8, 2025 6:09 am ET1min read
CLLS--
Cellectis (CLLS) reported 100,325,229 shares in its capital structure as of July 31, 2025, with 89,428,630 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth. The company specializes in gene-editing platforms for life-saving cell and gene therapies, with a focus on allogeneic CAR T immunotherapies in oncology. Headquartered in Paris, France, Cellectis is listed on Euronext Growth and the Nasdaq Global Market under the ticker CLLS.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet